Review links electroconvulsive therapy with fewer catatonia symptoms in Down syndrome regression disorder
The analysis combined reports from 27 patients, but the small, uncontrolled evidence base cannot establish that electroconvulsive therapy caused the improvement.
High evidenceReviewInterpret with caution
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
The researchers combined a case series from Vanderbilt University Medical Center with 22 patients described in 14 earlier studies. In total, the analysis included 27 people with Down syndrome regression disorder and catatonia, a condition involving changes in movement, behavior, and functioning.
Among the patients with available rating-scale data, average catatonia scores were lower after electroconvulsive therapy than before it. No severe adverse events were reported in the included reports. Because there was no comparison group and the studies were small and varied, the findings do not establish that electroconvulsive therapy itself caused the changes.
The question reviewed
This human systematic review and case-series analysis examined the reported use of electroconvulsive therapy for catatonia in people with Down syndrome regression disorder. It included five patients treated at Vanderbilt University Medical Center and 22 additional patients from 14 published studies, for 27 patients overall. Bush-Francis Catatonia Rating Scale scores were available before treatment for 17 patients and after treatment for 15 patients, drawn from seven sites or studies. The researchers used a statistical model to compare expected scores before and after treatment.
Key conclusions
The mean reported Bush-Francis Catatonia Rating Scale score was 17.40 before electroconvulsive therapy and 4.40 afterward. The analysis found a statistically significant difference in expected scores, with a reported estimated change of -13.00 and p < 0.001. This pattern was associated with fewer measured catatonia symptoms after treatment, but the study design cannot determine whether electroconvulsive therapy caused the improvement. No severe adverse events were reported, although the abstract does not provide detailed information about how adverse events were assessed or how long patients were followed.
Where this may apply
These findings may be relevant to people with Down syndrome regression disorder and catatonia who resemble the patients described in the included reports. They do not necessarily apply to people with Down syndrome who do not have regression disorder or catatonia, to other causes of catatonia, or to people with different health characteristics. The review does not provide enough evidence to determine outcomes for all patients, and it should not be read as proof that electroconvulsive therapy will produce the same results in any individual.
What this could mean
Down syndrome regression disorder can involve substantial functional decline, and catatonia may be part of this condition. The review brings together limited human evidence about electroconvulsive therapy in this specific setting and identifies a pattern of improvement in reported catatonia scores. It does not establish the treatment’s effectiveness for every person with Down syndrome regression disorder, and it does not provide enough information to determine longer-term outcomes or risks.
Limitations & evidence assessment
The evidence was based on only 27 patients, including a five-person case series and previously published case-based studies, rather than a randomized comparison. There was no control group, so changes could have been related to other treatments, recovery over time, differences between patients, or how outcomes were measured. Catatonia scores were not available for every patient before and after treatment, and the included reports came from different sites and studies. The abstract states that no severe adverse events were reported, but it provides limited detail about other adverse events, follow-up duration, treatment methods, and possible publication or reporting bias. The abstract also says more research is needed, indicating that the evidence base remains limited despite the systematic-review design.
Why this evidence level: Systematic review aggregating primary studies with explicit methodology.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
Journal of Autism and Developmental Disorders · 2026 · DOI: 10.1007/s10803-026-07500-3
This review examines pancreatic cystic lesions, especially intraductal papillary mucinous neoplasms (IPMNs), and how imaging may help distinguish them from other cysts. It discusses signs associated with cancer arising from an IPMN and the possibility of a separate pancreatic cancer developing elsewhere in the pancreas. The article is a review, not a new study of a defined group of patients.
A cluster-randomized trial in India studied 1,507 adults with heart failure with reduced ejection fraction. Compared with usual care, a nurse-coordinated program supported by mobile health tools was associated with more days alive and out of the hospital and fewer deaths during two years of follow-up.
A narrative review examined the role of radioactive iodine therapy in children and adolescents with differentiated thyroid cancer. It reported that the treatment may be most useful for selected patients at intermediate or high risk, particularly when cancer has spread to the lungs and still absorbs iodine, while routine use in lower-risk children has not shown a survival advantage in the reviewed evidence.
